Iceland· IS-EU/1/18/1271/002-005
Hemlibra
A emicizumab product containing emicizumabum inn, registered in Iceland by Roche Registration GmbH*. The same ATC class is registered in 15 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Emicizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC B02BX06 (emicizumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Emicizumab · ATC B02BX06
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of emicizumab costs, country by country.
Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Emicizumab · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1013.07
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Emicizumabum INN
- Manufacturer
- Roche Registration GmbH*
- Country
- Iceland (IS)
- ATC code
- B02BX06
- ATC class
- Emicizumab
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 3
3 priced- ean1046120,4 ml x1 hglISK 564414
- ean1358811 ml x1 hglISK 1399379
- ean1993330,7 ml x1 hglISK 978686
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for emicizumab.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Emicizumab · interactions on record
4 records
- 1 severe
- 3 moderate
Most severe, free to view
- Faktor VIII-Inhibitor Bypass Aktivität - FEIBAB02BD03severe
- Coagulation factor VIIIB02BD02moderate
- Coagulation factor VIIaB02BD08moderate
- Octocog alfaB02BD28moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Emicizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumHemlibra 150 mg/mlRoche Registration
- SwitzerlandHemlibra
- CzechiaHEMLIBRARoche Registration GmbH, Grenzach-Wyhlen
- SpainHEMLIBRA 150 MG/ML SOLUCION INYECTABLERoche Registration Gmbh
- NorwayHemlibraRoche Registration GmbH
- PolandHemlibraRoche Registration GmbH
- SwedenHemlibra 150 mg/ml Injektionsvätska, lösningRoche Registration GmbH
- Japanエミシズマブ（遺伝子組換え）中外製薬
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Hemlibra
- Norway · Hemlibra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/04c38ec9-3b04-4192-89b2-da45c182af57 GET /v1/drugs/04c38ec9-3b04-4192-89b2-da45c182af57?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "B02BX06",
"marketed": true,
"strength": "150 mg/ ml",
"ma_number": "EU/1/18/1271/002-005",
"substance": "Emicizumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43154"
}See everything about emicizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.